Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines

Source Summary

BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, today announced a multi-year collaboration with Novartis to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. The collaboration expands the existing relationship between the companies and reflects a shared commitment to unlock the full value of induced proximity approac